News stories about Iradimed (NASDAQ:IRMD) have been trending somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Iradimed earned a media sentiment score of 0.07 on Accern’s scale. Accern also assigned media stories about the medical equipment provider an impact score of 45.1417659455139 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Iradimed (NASDAQ:IRMD) traded down $0.20 during trading hours on Monday, hitting $15.50. The company’s stock had a trading volume of 32,200 shares, compared to its average volume of 32,733. The firm has a market cap of $163.61, a price-to-earnings ratio of 119.24 and a beta of 1.62. Iradimed has a 52-week low of $7.85 and a 52-week high of $15.85.
Iradimed (NASDAQ:IRMD) last posted its quarterly earnings results on Monday, October 30th. The medical equipment provider reported $0.07 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.28) by $0.35. The firm had revenue of $5.69 million for the quarter, compared to analyst estimates of $5.60 million. Iradimed had a return on equity of 4.58% and a net margin of 6.51%. The business’s quarterly revenue was down 25.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.14 EPS. sell-side analysts predict that Iradimed will post 0.05 earnings per share for the current fiscal year.
In related news, Director Monty K. Allen sold 1,898 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $13.95, for a total transaction of $26,477.10. Following the transaction, the director now directly owns 9,062 shares of the company’s stock, valued at approximately $126,414.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 60.10% of the stock is currently owned by insiders.
IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.
Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.